383 related articles for article (PubMed ID: 18192084)
21. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease.
Schwab C; Hosokawa M; McGeer PL
Exp Neurol; 2004 Jul; 188(1):52-64. PubMed ID: 15191802
[TBL] [Abstract][Full Text] [Related]
22. Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice.
Eckert A; Hauptmann S; Scherping I; Rhein V; Müller-Spahn F; Götz J; Müller WE
Neurodegener Dis; 2008; 5(3-4):157-9. PubMed ID: 18322377
[TBL] [Abstract][Full Text] [Related]
23. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.
DeMattos RB; Bales KR; Cummins DJ; Paul SM; Holtzman DM
Science; 2002 Mar; 295(5563):2264-7. PubMed ID: 11910111
[TBL] [Abstract][Full Text] [Related]
24. Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice.
Hartmann J; Erb C; Ebert U; Baumann KH; Popp A; König G; Klein J
Neuroscience; 2004; 125(4):1009-17. PubMed ID: 15120860
[TBL] [Abstract][Full Text] [Related]
25. Metallothionein-I and -III expression in animal models of Alzheimer disease.
Carrasco J; Adlard P; Cotman C; Quintana A; Penkowa M; Xu F; Van Nostrand WE; Hidalgo J
Neuroscience; 2006 Dec; 143(4):911-22. PubMed ID: 17027170
[TBL] [Abstract][Full Text] [Related]
26. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice.
Grueninger F; Bohrmann B; Czech C; Ballard TM; Frey JR; Weidensteiner C; von Kienlin M; Ozmen L
Neurobiol Dis; 2010 Feb; 37(2):294-306. PubMed ID: 19781645
[TBL] [Abstract][Full Text] [Related]
27. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical.
Lee HJ; Zhang Y; Zhu C; Duff K; Pardridge WM
J Cereb Blood Flow Metab; 2002 Feb; 22(2):223-31. PubMed ID: 11823720
[TBL] [Abstract][Full Text] [Related]
28. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease.
Fagan AM; Watson M; Parsadanian M; Bales KR; Paul SM; Holtzman DM
Neurobiol Dis; 2002 Apr; 9(3):305-18. PubMed ID: 11950276
[TBL] [Abstract][Full Text] [Related]
29. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.
Boissonneault V; Filali M; Lessard M; Relton J; Wong G; Rivest S
Brain; 2009 Apr; 132(Pt 4):1078-92. PubMed ID: 19151372
[TBL] [Abstract][Full Text] [Related]
30. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease.
Garcia-Alloza M; Robbins EM; Zhang-Nunes SX; Purcell SM; Betensky RA; Raju S; Prada C; Greenberg SM; Bacskai BJ; Frosch MP
Neurobiol Dis; 2006 Dec; 24(3):516-24. PubMed ID: 17029828
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
32. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease.
Lafay-Chebassier C; Paccalin M; Page G; Barc-Pain S; Perault-Pochat MC; Gil R; Pradier L; Hugon J
J Neurochem; 2005 Jul; 94(1):215-25. PubMed ID: 15953364
[TBL] [Abstract][Full Text] [Related]
33. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation.
Cheng IH; Palop JJ; Esposito LA; Bien-Ly N; Yan F; Mucke L
Nat Med; 2004 Nov; 10(11):1190-2. PubMed ID: 15502844
[TBL] [Abstract][Full Text] [Related]
34. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.
Nilsberth C; Westlind-Danielsson A; Eckman CB; Condron MM; Axelman K; Forsell C; Stenh C; Luthman J; Teplow DB; Younkin SG; Näslund J; Lannfelt L
Nat Neurosci; 2001 Sep; 4(9):887-93. PubMed ID: 11528419
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
36. Reduced brain volumes in mice expressing APP-Austrian mutation but not in mice expressing APP-Swedish-Austrian mutations.
Van Broeck B; Vanhoutte G; Cuijt I; Pereson S; Joris G; Timmermans JP; Van der Linden A; Van Broeckhoven C; Kumar-Singh S
Neurosci Lett; 2008 Dec; 447(2-3):143-7. PubMed ID: 18840503
[TBL] [Abstract][Full Text] [Related]
37. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease.
El Tannir El Tayara N; Delatour B; Le Cudennec C; Guégan M; Volk A; Dhenain M
Neurobiol Dis; 2006 Apr; 22(1):199-208. PubMed ID: 16337798
[TBL] [Abstract][Full Text] [Related]
38. Intraneuronal amyloid-beta plays a role in mediating the synergistic pathological effects of apoE4 and environmental stimulation.
Levi O; Dolev I; Belinson H; Michaelson DM
J Neurochem; 2007 Nov; 103(3):1031-40. PubMed ID: 17666042
[TBL] [Abstract][Full Text] [Related]
39. Extracellular amyloid formation and associated pathology in neural grafts.
Meyer-Luehmann M; Stalder M; Herzig MC; Kaeser SA; Kohler E; Pfeifer M; Boncristiano S; Mathews PM; Mercken M; Abramowski D; Staufenbiel M; Jucker M
Nat Neurosci; 2003 Apr; 6(4):370-7. PubMed ID: 12598899
[TBL] [Abstract][Full Text] [Related]
40. Novel aspects of accumulation dynamics and A beta composition in transgenic models of AD.
Lewis HD; Beher D; Smith D; Hewson L; Cookson N; Reynolds DS; Dawson GR; Jiang M; Van der Ploeg LH; Qian S; Rosahl TW; Kalaria RN; Shearman MS
Neurobiol Aging; 2004 Oct; 25(9):1175-85. PubMed ID: 15312963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
